NASDAQ:NRXP

NRx Pharmaceuticals - NRXP Stock Forecast, Price & News

$1.23

-0.02 (-1.60%)

(As of 01/27/2023 12:00 AM ET)

Add

Compare

Today's Range: $1.18
▼
$1.26
50-Day Range: $1.01
▼
$1.48
52-Week Range: $0.49
▼
$3.54

Volume: 246,822 shs
Average Volume: 338,708 shs
Market Capitalization: $83.26 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.00

Institutional Ownership

NRx Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 143.9% Upside
$3.00 Price Target
Short Interest: Healthy
3.30% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Balanced
Insiders Both Buying and Selling
Proj. Earnings Growth: Growing
From ($0.67) to ($0.62) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.50 out of 5 stars

Medical Sector

162nd out of 1,055 stocks

Pharmaceutical Preparations Industry

73rd out of 519 stocks

3.5

Analyst's Opinion

Consensus Rating
NRx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.00, NRx Pharmaceuticals has a forecasted upside of 143.9% from its current price of $1.23.
Amount of Analyst Coverage
NRx Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
3.30% of the float of NRx Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
NRx Pharmaceuticals has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in NRx Pharmaceuticals has recently decreased by 7.09%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
NRx Pharmaceuticals does not currently pay a dividend.
Dividend Growth
NRx Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NRXP.

3.3

News and Social Media Coverage

News Sentiment
NRx Pharmaceuticals has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for NRx Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
12 people have searched for NRXP on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, NRx Pharmaceuticals insiders have sold just slightly more of their company's stock than they have bought. Specifically, they have bought $441,204.00 in company stock and sold $504,956.00 in company stock. It is common for insiders to sell company stock at intervals simply to diversify their holdings.
Percentage Held by Insiders
25.70% of the stock of NRx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 6.09% of the stock of NRx Pharmaceuticals is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for NRx Pharmaceuticals are expected to grow in the coming year, from ($0.67) to ($0.62) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of NRx Pharmaceuticals is -2.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of NRx Pharmaceuticals is -2.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
NRx Pharmaceuticals has a P/B Ratio of 3.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About NRx Pharmaceuticals (NASDAQ:NRXP) Stock

NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded on September 18, 2017 and is headquartered in Wilmington, DE.

Receive NRXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

NRXP Stock News Headlines

January 19, 2023 | finance.yahoo.com

NRx Pharmaceuticals Provides Progress Update on Interactions with the FDA regarding Path to NDA Submission for NRX-101

January 5, 2023 | finance.yahoo.com

NRx Pharmaceuticals to Present Scientific Update at the 6th Annual Sachs Associates Neuroscience Innovation Forum in Conjunction with the 2023 J.P. Morgan Healthcare Conference

January 27, 2023 | Porter & Company (Ad)

Is This The End of Capitalism?

EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…

January 3, 2023 | finance.yahoo.com

NRx Pharmaceuticals Initiates Phase 3 Trial Treating Patients with Bipolar Depression with Acute Suicidality - First Clinical Site Contracted

December 5, 2022 | finance.yahoo.com

NRx Pharmaceuticals Announces the Appointment of Carrie M. Carretta, PhD, APN-BC, AHN-BC, PMHNP, Senior Vice President of Clinical Development and Medical Affairs

December 2, 2022 | finance.yahoo.com

NRx Receives Nasdaq Notice of Listing Compliance

November 24, 2022 | au.finance.yahoo.com

The Independent Director of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), Chaim Hurvitz, Just Bought 30% More Shares

November 14, 2022 | bizjournals.com

NRx agrees to relinquish rights to experimental Covid-19 therapy in settlement with Relief Therapeutics

January 27, 2023 | Porter & Company (Ad)

Is This The End of Capitalism?

EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…

November 14, 2022 | finance.yahoo.com

NRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

November 14, 2022 | markets.businessinsider.com

NRx Pharma To Transfer Aviptadil Development Program Assets To Relief Therapeutics

November 12, 2022 | msn.com

Earnings Outlook For NRX Pharmaceuticals

November 9, 2022 | seekingalpha.com

NRx Pharma announces commercial production of drug targeted at suicidal depression

November 9, 2022 | finance.yahoo.com

NRx Pharmaceuticals Produces First Phase 3-stage NRX-101 Drug Made Using Commercial Process

November 7, 2022 | finance.yahoo.com

NRx Pharmaceuticals Closes $11 Million Unsecured Debt Financing

September 23, 2022 | finance.yahoo.com

NRx Pharmaceuticals, Inc. (NRXP)

September 7, 2022 | wsj.com

NRX Pharmaceuticals Inc.

August 22, 2022 | finance.yahoo.com

NRx, Relief Therapeutics reach tentative agreement to resolve litigation tied to Covid-19 therapy candidate

August 17, 2022 | investing.com

NRx Pharmaceuticals, Inc. Reports Q2 Loss of $0.10

August 16, 2022 | seekingalpha.com

NRx Pharmaceuticals, Inc. (NRXP) CEO Stephen Willard on Q2 2022 Results - Earnings Call Transcript

August 16, 2022 | benzinga.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NRx Pharmaceuticals, Inc. - NRXP; NRXPW

August 15, 2022 | finance.yahoo.com

NRx Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Results Focusing on Reactivation & Advancement of its Psychiatry Franchise

August 10, 2022 | finance.yahoo.com

/C O R R E C T I O N -- NRx Pharmaceuticals, Inc./

August 3, 2022 | marketwatch.com

Thinking about buying stock in Ford Motor, Missfresh, Intel Corp, Ontrak, or NRX Pharmaceuticals?

July 29, 2022 | benzinga.com

Thinking about buying stock in Athersys, Geovax Labs, NRX Pharmaceuticals, Marathon Digital, or Trade Desk?

July 13, 2022 | bizjournals.com

NRx Pharmaceuticals names new CEO

July 13, 2022 | nasdaq.com

NRx Pharmaceuticals Appoints Stephen Willard As CEO

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive NRXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

NRXP Company Calendar

Last Earnings: 11/14/2022
Today: 1/27/2023
Next Earnings (Estimated): 3/30/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:NRXP
CUSIP: N/A
CIK: 1719406
Web: www.bigrockpartners.com
Phone: (484) 254-6134
Fax: N/A
Employees: 2
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $3.00
High Stock Price Forecast: $4.00
Low Stock Price Forecast: $2.00
Forecasted Upside/Downside: +143.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.55)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-93,060,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -275.44%
Return on Assets: -195.11%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.08
Quick Ratio: 3.08

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.35 per share
Price / Book: 3.51

Miscellaneous

Outstanding Shares: 67,691,000
Free Float: 50,294,000
Market Cap: $83.26 million
Optionable: Not Optionable
Beta: 0.97

Key Executives

Stephen H. Willard
Chief Executive Officer & Director

Robert Besthof
Chief Commercial Officer & Head-Operations

Seth L. van Voorhees
Chief Financial Officer & Treasurer

Carrie M. Carretta
Senior VP-Clinical Development & Medical Affairs

Dennis K. McBride
Chief Strategy Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NRXP Stock - Frequently Asked Questions

Should I buy or sell NRx Pharmaceuticals stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NRx Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NRXP shares.
View NRXP analyst ratings or view top-rated stocks.
What is NRx Pharmaceuticals' stock price forecast for 2023?: 2 Wall Street analysts have issued 12-month target prices for NRx Pharmaceuticals' shares. Their NRXP share price forecasts range from $2.00 to $4.00. On average, they anticipate the company's stock price to reach $3.00 in the next year. This suggests a possible upside of 140.0% from the stock's current price.
View analysts price targets for NRXP or view top-rated stocks among Wall Street analysts.
How have NRXP shares performed in 2023?: NRx Pharmaceuticals' stock was trading at $1.11 on January 1st, 2023. Since then, NRXP shares have increased by 12.6% and is now trading at $1.25.
View the best growth stocks for 2023 here.
When is NRx Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our NRXP earnings forecast.

How were NRx Pharmaceuticals' earnings last quarter?: NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) posted its quarterly earnings results on Monday, November, 14th. The company reported ($0.14) EPS for the quarter, hitting the consensus estimate of ($0.14).
What is NRx Pharmaceuticals' stock symbol?: NRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "NRXP."
Who are NRx Pharmaceuticals' major shareholders?: NRx Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Exchange Traded Concepts LLC (0.04%). Insiders that own company stock include Alessandra Daigneault, Chaim Hurvitz, Daniel C Javitt, Jonathan C Javitt, Patrick John Flynn, Robert Besthof, Stephen H Willard and Voorhees Seth Van.
View institutional ownership trends.
How do I buy shares of NRx Pharmaceuticals?: Shares of NRXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is NRx Pharmaceuticals' stock price today?: One share of NRXP stock can currently be purchased for approximately $1.25.
How much money does NRx Pharmaceuticals make?: NRx Pharmaceuticals (NASDAQ:NRXP) has a market capitalization of $84.61 million. The company earns $-93,060,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis.
How can I contact NRx Pharmaceuticals?: NRx Pharmaceuticals' mailing address is 2645 N. Federal Highway Suite 230, Delray Beach FL, 33483. The official website for the company is www.bigrockpartners.com. The company can be reached via phone at (484) 254-6134 or via email at rsheffield@nrxpharma.com.

This page (NASDAQ:NRXP) was last updated on 1/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

NRx Pharmaceuticals - NRXP Stock Forecast, Price & News

NRx Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About NRx Pharmaceuticals (NASDAQ:NRXP) Stock

NRXP Stock News Headlines

NRXP Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

NRXP Stock - Frequently Asked Questions

Overall MarketRank^™